A growing body of evidence is shifting expert opinion toward supporting MS treatment during pregnancy, emphasizing ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III ...

People around the world are set to benefit from new breakthroughs in AI-driven drug discovery to tackle previously untreatable diseases and transforming patient outcomes using British AI and research ...

Genentech’s short film draws on the experiences of multiple families caring for children with hemophilia A, seeking to ...

Genentech has announced plans to build a new biotechnology manufacturing plant in Holly Springs, North Carolina. The company, ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall ...

With a background in biochemistry, Erica Taylor admits her route into marketing is not common, but it has given her a unique ...